Asia
Eisai Co., Ltd. has announced that its in-house discovered fibroblast growth factor receptor tyrosine kinase inhibitor E7090 has been granted the SAKIGAKE designation by Japan’s Ministry of Health, Labour and Welfare for the treatment of unresectable biliary tract cancer with FGFR2 gene fusion.
Activities held in partnership with Dubai Health Authority
It is with deep regret that the Agency for Science, Technology and Research announces the passing of Dr Sydney Brenner, Honorary Singapore Citizen, and A*STAR Senior Fellow, early this morning.
Motion Sickness Solution Now Available in Convenience Stores
Sino-American relations continue to show signs of strain after the administration of President Donald Trump ordered the Chinese majority owner of healthcare company PatientsLikeMe to sell his stake.
Cytovant licenses East Asian rights for a research-stage T cell receptor (TCR) against tumor antigen NY-ESO-1 as well as rights for Medigene’s dendritic cell (DC) vaccine for the treatment of patients across East Asia
The U.S. Federal Trade Commission (FTC) won a suit against India-based scientific publisher, Omics International, alleging that the publisher operated hundreds of fake scientific journals with deceptive business practices.
Partnering with Hong Kong-based Sinovant Sciences, which is one of Ramaswamy’s “vant” companies, Roivant and Sinovant are launching a company called Cytovant Sciences.
TLC announced financial results for the fourth quarter and full year ended December 31, 2018, and provided a business update.
During a presentation at the American Association for Cancer Research meeting over the weekend, Astellas touted new overall survival data for Xospata.
PRESS RELEASES